Search
for
Sort by
Research 121–150 of 1000+
- Integrated single-cell chromatin and transcriptomic analyses of human scalp identify gene-regulatory programs and critical cell types for hair and skin diseases
- Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs
- Finding Long-COVID: temporal topic modeling of electronic health records from the N3C and RECOVER programs
- Author response: Selective amputation of the pharynx identifies a FoxA-dependent regeneration program in planaria
- Low-level Laser Therapy with Novel Array of Light Source and Individualized Program for Treatment of Androgenetic Alopecia: A 16-week, Randomized, Double-blind, Sham Device-controlled Study
- Bone morphogenetic protein signaling drives rete ridge morphogenesis: a distinct epidermal appendage program
- 172 Mapping the global landscape of therapeutic patient education and self-management support programs in psoriasis: a qualitative study
- Decision letter: Selective amputation of the pharynx identifies a FoxA-dependent regeneration program in planaria
- Animal Models and the Developmental Origins of Polycystic Ovary Syndrome: Increasing Evidence for the Role of Androgens in Programming Reproductive and Metabolic Dysfunction
- Severe hair loss associated with psyc hotropic drugs in psychiatric inpatients—Data from an observational pharmacovigilance program in German-speaking countries
- Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Eyebrows and Eyelashes Regrowth Across Different SALT Response Thresholds in Patients with Alopecia Areata: Outcomes from the BRAVE AA Clinical Program
- Induction of a Regenerative State in Hair Follicle Stem Cells by Helium Plasma-Activated Medium Through Coordinated Regulation of Regenerative Programs
- 77015 Subgroup Analysis of Efficacy of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata From the UP-AA Phase 3 Program
- 61346 Baseline Psychosocial Impact of Disease in Patients with Severe Alopecia Areata Treated with Baricitinib Recruited from the US Customer Support Program
- 63407 A Descriptive Analysis of Patients With Moderate-to-Severe Atopic Dermatitis and Comorbid Alopecia Areata in the Abrocitinib JADE Clinical Program
- Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- 42276 Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: A Post-hoc Analysis of End-Of-Study Program Data Relating to Major Adverse Cardiovascular Events
- 707 Informative leaflet about neovaginal dilatation after MtF reassignment surgery: the importance of correct management of dilatation programme
- 244 Defective maintenance of hair follicle stem cells through COL17A1 loss orchestrates the hair follicle aging program
- Message from Paul J. McAndrews, Program Chair of the 2010 Annual Meeting
- Message from Paul J. McAndrews, Program Chair of the 2010 Annual Meeting
- Message from Paul J. McAndrews, Program Chair of the 2010 Annual Meeting
- 76957 Efficacy and Safety of Upadacitinib in Adolescents and Adults with Severe Alopecia Areata: A Subgroup Analysis of the UP-AA Phase 3 Clinical Program
- 75810 Long-term efficacy, complete scalp hair regrowth, and normal body hair and nails in patients with alopecia areata (AA) receiving ritlecitinib 50 mg once daily up to 3 years in the ALLEGRO clinical trial program
- Farmácia dos Clérigos - Porto e nos Serviços Farmacêuticos da University College Hospital - Londres, Reino Unido, ao abrigo do programa Erasmus+
- 169 TEDAR, a skin-specific long non-coding RNA, orchestrates the late epidermal differentiation program in the human epidermis
- Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
- Farmácia Monte da Virgem - Vila Nova de Gaia e nos Serviços Farmacêuticos do Hospital Klinica Bolnica Dubrava - Zagreb, Croácia, ao abrigo do programa Erasmus+
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program